Business Description
Structure Therapeutics is a clinical-stage pharmaceutical company focused on developing oral pill-based treatments for chronic conditions that currently lack good solutions, including obesity and lung disease. Its most advanced drug candidate, GSBR-1290, targets a key metabolic receptor and is currently being tested in two mid-stage clinical trials for obesity and related conditions. The company has several other drug programs in earlier stages of development, targeting a range of biological pathways involved in metabolism and tissue scarring. Founded in 2016 and based in South San Francisco, Structure Therapeutics operates across the United States and globally.
